ATE214936T1 - Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren - Google Patents

Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren

Info

Publication number: ATE214936T1
Authority: AT; Austria
Prior art keywords: pharmaceutically acceptable; oxidized glutathione; salt form; acceptable salt; production
Prior art date: 1995-12-14

Application number

AT96941915T

Other languages

English (en)

Inventor

Mark Borisovich Balazovsky

Leonid Andreevich Kozhemyakin

Original Assignee

Novelos Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-14

Filing date

1996-12-10

Publication date

2002-04-15

1995-12-14 Priority claimed from RU95120403/14A external-priority patent/RU2089179C1/ru

1996-12-10 Application filed by Novelos Therapeutics Inc filed Critical Novelos Therapeutics Inc

2002-04-15 Application granted granted Critical

2002-04-15 Publication of ATE214936T1 publication Critical patent/ATE214936T1/de

Links

108010053070 Glutathione Disulfide Proteins 0.000 title abstract 5
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 title abstract 5
YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 title abstract 5
102000004127 Cytokines Human genes 0.000 title abstract 3
108090000695 Cytokines Proteins 0.000 title abstract 3
230000003394 haemopoietic effect Effects 0.000 title 1
150000003839 salts Chemical group 0.000 abstract 4
230000002607 hemopoietic effect Effects 0.000 abstract 2
239000004606 Fillers/Extenders Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)

AT96941915T 1995-12-14 1996-12-10 Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren ATE214936T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
RU95120403/14A RU2089179C1 (ru)	1995-12-14	1995-12-14	Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
PCT/RU1996/000226 WO1997021443A1 (en)	1995-12-14	1996-08-08	Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
PCT/RU1996/000340 WO1997021444A1 (en)	1995-12-14	1996-12-10	Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof

Publications (1)

Publication Number	Publication Date
ATE214936T1 true ATE214936T1 (de)	2002-04-15

Family

ID=26653679

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96941915T ATE214936T1 (de)	1995-12-14	1996-12-10	Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren

Country Status (8)

Country	Link
EP (1)	EP0869809B1 (de)
JP (2)	JP2000515111A (de)
AT (1)	ATE214936T1 (de)
AU (1)	AU1113097A (de)
CA (1)	CA2239874A1 (de)
DE (1)	DE69620233T2 (de)
ES (1)	ES2174124T3 (de)
WO (1)	WO1997021444A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU746946B2 (en) *	1997-03-21	2002-05-09	Shiseido Company Ltd.	Immunopotentiators
IL123887A0 (en) *	1997-04-02	1998-10-30	Sankyo Co	Dithiolan derivatives their use and pharmaceutical compositions containing the same
JP2002509715A (ja) *	1998-03-30	2002-04-02	イ・デ・エム・イミュノ−デジネ・モレキュル	刺激された単球に由来する細胞、その調製及び用途
JP2000169371A (ja) *	1998-10-02	2000-06-20	Sankyo Co Ltd	ジチオラン誘導体を含有する医薬
RU2144374C1 (ru) *	1998-11-23	2000-01-20	Закрытое акционерное общество "ВАМ"	Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US6312734B1 (en) *	1998-11-23	2001-11-06	Novelos Therapeutics, Inc.	Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US20070142267A1 (en)	1998-11-23	2007-06-21	Novelos Therapeutics, Inc.	Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2229892C2 (ru) *	2001-06-08	2004-06-10	Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии"	Способ лечения туберкулеза легких
US7173013B2 (en)	2001-06-08	2007-02-06	Sciclone Pharmaceuticals, Inc.	Treatment of tuberculosis using immunomodulator compounds
EP1596756A4 (de) *	2003-01-23	2009-11-11	Supernus Pharmaceuticals Inc	Mittel zur absorptionserhöhung
RU2482868C1 (ru) *	2011-12-30	2013-05-27	Общество С Ограниченной Ответственностью "Ива Фарм"	Средство для лечения диабета, фармацевтическая композиция и способ лечения заболеваний
ES2659199T3 (es) *	2012-09-28	2018-03-14	Kyowa Hakko Bio Co., Ltd.	Agente para aumentar la inmunidad que contiene glutatión
RU2545900C2 (ru) *	2013-05-07	2015-04-10	Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук	Способ диагностики апоптоза лимфоцитов
RU2540500C2 (ru) *	2013-05-07	2015-02-10	Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук	Способ прогнозирования ранней стадии апоптоза
RU2659161C1 (ru)	2017-11-17	2018-06-28	Общество С Ограниченной Ответственностью "Ива Фарм"	Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид
CN114617899B (zh) *	2022-04-14	2023-10-20	苏州大学附属儿童医院	S-腺苷甲硫氨酸在制备治疗脓毒血症相关性脑病药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61277619A (ja) *	1985-06-04	1986-12-08	Otsuka Pharmaceut Factory Inc	肝疾患治療剤
JP2921124B2 (ja) *	1990-12-28	1999-07-19	千寿製薬株式会社	酸化型グルタチオンアルキルエステル
US5977073A (en) *	1991-06-06	1999-11-02	Life Sciences' Technologies, Inc.	Nutrient composition for treatment of immune disorders
US5618823A (en) *	1992-06-24	1997-04-08	Boehringer Mannheim Italia S.P.A.	Glutathione as chemoprotective agent
GB9303854D0 (en) *	1993-02-25	1993-04-14	Holt John A G	Method for enhancing t-cell count

1996
- 1996-12-10 CA CA002239874A patent/CA2239874A1/en not_active Abandoned
- 1996-12-10 AU AU11130/97A patent/AU1113097A/en not_active Abandoned
- 1996-12-10 AT AT96941915T patent/ATE214936T1/de active
- 1996-12-10 WO PCT/RU1996/000340 patent/WO1997021444A1/en not_active Ceased
- 1996-12-10 DE DE69620233T patent/DE69620233T2/de not_active Expired - Lifetime
- 1996-12-10 ES ES96941915T patent/ES2174124T3/es not_active Expired - Lifetime
- 1996-12-10 JP JP09521965A patent/JP2000515111A/ja not_active Withdrawn
- 1996-12-10 EP EP96941915A patent/EP0869809B1/de not_active Expired - Lifetime
2007
- 2007-09-13 JP JP2007238577A patent/JP2008001722A/ja active Pending

Also Published As

Publication number	Publication date
ES2174124T3 (es)	2002-11-01
DE69620233D1 (de)	2002-05-02
EP0869809A1 (de)	1998-10-14
DE69620233T2 (de)	2002-11-14
WO1997021444A1 (en)	1997-06-19
JP2000515111A (ja)	2000-11-14
EP0869809B1 (de)	2002-03-27
CA2239874A1 (en)	1997-06-19
JP2008001722A (ja)	2008-01-10
AU1113097A (en)	1997-07-03

Legal Events

Date	Code	Title	Description
2002-08-15	UEP	Publication of translation of european patent specification

Publication	Publication Date	Title
DE69620233D1 (de)	2002-05-02	Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren
Skinner et al.	1996	A preliminary study of the effects of laser radiation on collagen metabolism in cell culture
GEP20002146B (en)	2000-06-25	Therapeutic Peptide Derivatives
EP0209689A3 (en)	1989-12-20	Use of tetrahydrobiopterins in the treatment of infantile autism
BR8804370A (pt)	1989-03-21	Dispositivo eletroterapeutico de baixa frequencia
DE69722426D1 (de)	2003-07-03	Isobutylgaba und dessen derivate zur schmerzbehandlung
ATE227587T1 (de)	2002-11-15	Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
ES2166783T3 (es)	2002-05-01	Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
EP0151989A3 (en)	1986-10-08	Means for the treatment of cardiac diseases
EP1041880A4 (de)	2006-04-12	Verabreichung von arginin zur erzielung eines wohltuenden effektes
AU6178198A (en)	1998-09-22	Method of treating a tumor
PT1119393E (pt)	2003-08-29	Estimulacao electromagnetica de tecido de cartilagem utilizando fgf
DE69621243D1 (de)	2002-06-20	Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
ATE393631T1 (de)	2008-05-15	Peptid und dessen kosmetische oder dermatologische verwendung zur verbesserung der haftung zwischen hautzellen
IT1258069B (it)	1996-02-20	Composizione per uso topico avente attivita' di stimolo per la ricrescita, di rinvigorimento, di prevenzione dell'ingrigimento e di ripigmentazione naturale dei capelli
ATE198271T1 (de)	2001-01-15	Syndecan-stimulierung der zellulären differenzierung
DE69110615D1 (de)	1995-07-27	Verwendung von Aminosäuren zum Schutz von ischemischem Herzgewebe und dessen metabolischer Wiederherstellung.
ATE346863T1 (de)	2006-12-15	Verwendung von eif4e-bindungsreagenzien in der therapie
GEP20012377B (en)	2001-03-25	Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
RU94024337A (ru)	1996-05-10	Антиметастатическое средство
AU7373196A (en)	1997-04-28	Combination of temozolomide and alpha-ifn for the treatment of advanced cancer
RU2002113429A (ru)	2003-12-10	Способ лечения псориаза
RU97121729A (ru)	1999-08-20	Способ стимуляции репаративного остеогенеза
UA39768A (uk)	2001-06-15	Спосіб лікування хворих зі спазмом акомодації
DE59506911D1 (de)	1999-10-28	Verwendung von intravenös applizierbarem eisen zur therapie von tumorerkrankungen und/oder infektionskrankheiten